Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermal filler approved

This article was originally published in The Gray Sheet

Executive Summary

Sanofi-Aventis' injectable poly-L-lactic acid Sculptra Aesthetic receives supplemental PMA approval for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles, the company announced July 28. The approval was supported by a multi-center study that randomized 233 patients to either Sculptra or an approved human-derived collagen, the company said in a July 29 release. Results showed that Sculptra effects were maintained for up to 25 months after the last treatment, versus three months with the human-derived collagen. Sculptra was originally approved in 2004 for facial lipoatrophy

You may also be interested in...



News In Brief

Valeant gains Sculptra for wrinkles

Health Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Topics

UsernamePublicRestriction

Register

MT027733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel